Endologix, Inc. is a U.S.-based medical device company specializing in minimally invasive therapies for abdominal aortic aneurysms (AAA). The firm designs, develops and commercializes endovascular stent graft systems intended to treat life-threatening aneurysms of the abdominal aorta. Through its proprietary delivery technologies, Endologix aims to improve procedural efficiency and long-term patient outcomes relative to traditional open surgical repair.
The company’s core product portfolio centers on the AFX® Endovascular AAA System, which features a modular graft design and a unique anatomical fixation mechanism. Endologix also developed the Nellix® Endovascular Aneurysm Sealing (EVAS) System, reflecting its focus on novel sealing approaches. In addition, the firm offers a range of supporting catheters, guidewires and polymer components that complement its aneurysm repair platforms.
Headquartered in Irvine, California, Endologix was founded in 1992 and has since expanded its commercial footprint through direct sales teams and distribution partners. Its therapies are utilized in hospitals and vascular centers across North America, Europe, Asia Pacific and Latin America. The company invests in clinical research collaborations and product development programs to refine device performance and broaden patient access.
Endologix maintains ongoing research initiatives to advance minimally invasive vascular solutions. By working with leading vascular surgeons and clinical investigators, the company seeks to address challenges in device delivery, procedural simplicity and long-term aneurysm exclusion. Through continued innovation and strategic partnerships, Endologix aims to enhance the standard of care for patients with abdominal aortic aneurysms worldwide.
AI Generated. May Contain Errors.
Free ELGXQ Stock Alerts